“We are excited to present data at ACR Convergence 2025 that validate DNASE1L3 as a novel therapeutic approach to degrade and inactivate NETs, a central driver of systemic inflammatory disorders,” said Anthony Aiudi, PharmD, Chief Executive Officer of Neutrolis. Unlike conventional approaches that broadly suppress immune responses, Neutrolis’ therapies harness the body’s own mechanisms to precisely degrade and inactivate NETs, offering broad potential across inflammatory disorders. The company’s lead program, based on DNASE1L3, is the first therapeutic strategy designed to dismantle pathogenic NETs and prevent their downstream inflammatory effects, restoring immune balance. By targeting this upstream driver of disease, Neutrolis aims to deliver transformational, disease-modifying treatments for conditions such as lupus, rheumatoid arthritis and other chronic immune disorders with high unmet need where current therapies remain inadequate. Investor Contact/ Media [email protected]